Participants in the study will undergo the open inguinal hernia mesh repair procedure, which is a common surgery to fix hernias in the groin area. The study will observe the patients for a period of three months after their surgery to assess the incidence of chronic pain. The goal is to determine if the timing of the TAP block can help prevent chronic pain and reduce the need for long-term use of pain-relief medications.

This study aims to provide valuable insights into pain management strategies for patients undergoing this type of hernia repair, potentially improving recovery experiences and outcomes. By understanding the impact of the TAP block’s timing, healthcare providers can better tailor pain management approaches to enhance patient comfort and reduce the risk of chronic pain after surgery.

In addition to chloroprocaine, other medications such as midazolam, fentanyl citrate, tramadol hydrochloride, paracetamol (also known as acetaminophen), and sevoflurane may be used during the study. These medications serve various roles, such as providing sedation, pain relief, or additional anesthesia if needed. The trial aims to assess how many patients do not require additional anesthesia during surgery, as well as other factors like the time it takes for the anesthetic to start working and how long it lasts.

The study is designed to gather information on the overall recovery of patients, including their pain levels and any side effects they might experience. The goal is to ensure that the anesthetic is both effective and safe for use in children undergoing these specific surgeries. Participants will be monitored closely throughout the process to ensure their well-being and to collect valuable data on the anesthetic’s performance.

Participants in the study will undergo open inguinal hernia surgery and receive either the combined block treatment or a single block treatment. The study will monitor the amount of pain relief medication needed during and after surgery, as well as the level of pain experienced by participants. Other aspects being observed include any feelings of nausea after surgery, the need for additional pain relief, and any complications that may arise during or after the procedure.

The trial will also assess participants’ overall satisfaction with their pain management and any feelings of anxiety or depression they may experience. The goal is to find the most effective way to manage pain and improve recovery for patients undergoing inguinal hernia surgery.

The medications used in this study include Ropivacaine Fresenius Kabi 7.5 mg/1 ml Solution injectable, which contains the active ingredient ropivacaine hydrochloride, and NaCl 0.9% B. Braun, oplossing voor injectie, which contains sodium chloride. These medications are administered through injection. The purpose of the study is to determine if the TAP block provides better pain relief than the local infiltration method.

Participants in the study will undergo their scheduled laparoscopic inguinal hernia repair surgery and will receive one of the two pain management techniques. The study will monitor the effectiveness of pain relief and the need for additional pain medication after surgery. The trial aims to find out which method offers superior pain control, potentially improving recovery experiences for patients undergoing this type of surgery.

The purpose of the study is to determine if not using antibiotics is just as effective as using them in preventing infections after hernia repair surgery. Participants in the study will either receive the antibiotic cefazolin or a placebo during their surgery. The study will monitor the development of any surgical site infections in both groups to compare the outcomes.

Throughout the study, participants will undergo their scheduled hernia repair surgery and will be observed for any signs of infection at the surgical site. The study aims to provide valuable information on whether antibiotics are necessary for all patients undergoing this type of surgery, potentially leading to changes in standard medical practices. The trial is expected to continue until the end of 2025.